Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension

被引：0

作者：

文莉 ^{[1
]}

机构：

[1] Dept Cardio-Pulm Cir,Shanghai Pulm Hosp,Med Sch,Tongji Univ

来源：

ChinaMedicalAbstracts(InternalMedicine) | 2014年 / 31卷 / 03期

关键词：

BNP; PAH; WHO; Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension;

D O I：

暂无

中图分类号：

R544.1 [高血压];

学科分类号：

摘要：

Objective To investigate long-term efficacy and safety of ambrisentan monotherapy in patients with pulmonary arterial hypertension(PAH).Methods Patients with PAH who received 2.5 mg or 5 mg of ambrisentan once daily between July 10,2011 and August 30,2012for at least 6 months were enrolled.The efficacy endpoints were changes in exercise capacity,World Health Organization(WHO)functional class and N-terminal probrain natriuretic peptide(NT-pro BNP)level,echocardiographic parameters.The safety endpoint was the safety of long-term ambrisentan administration,as defined by

引用

页码：160 / 161

页数：2

共 50 条

[1] Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension
Blalock, Shannon E.
Matulevicius, Susan
Mitchell, Laura C.
Reimold, Sharon
Warner, John
Peshock, Ronald
Torres, Fernando
Chin, Kelly M.
JOURNAL OF CARDIAC FAILURE, 2010, 16 (02) : 121 - 127
[2] Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension
Klinger, James R.
Oudiz, Ronald J.
Spence, Rebecca
Despain, Darrin
Dufton, Christopher
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (02): : 302 - 307
[3] Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension
Ben-Yehuda, Ori
Pizzuti, David
Brown, Andrea
Littman, Marcus
Gillies, Hunter
Henig, Noreen
Peschel, Tobias
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (01) : 80 - U105
[4] Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Oudiz, Ronald J.
Galie, Nazzareno
Olschewski, Horst
Torres, Fernando
Frost, Adaani
Ghofrani, Hossein A.
Badesch, David B.
McGoon, Michael D.
McLaughlin, Vallerie V.
Roecker, Ellen B.
Harrison, Brooke C.
Despain, Darrin
Dufton, Christopher
Rubin, Lewis J.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (21) : 1971 - 1981
[5] Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension
Oudiz, Ronald J.
CHEST, 2007, 132 (04) : 474S - 474S
[6] Long-Term Ambrisentan Therapy for Pulmonary Arterial Hypertension: Comparison by Etiology
Pulido, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
[7] Long-Term Ambrisentan Therapy in Patients with Pulmonary Arterial Hypertension: An Analysis by WHO Functional Class
Torres, F.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
[8] Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients
Sasayama, Shigetake
Satoh, Toru
Izumi, Tohru
Yoshida, Shunji
Kyotani, Shingo
Tahara, Nobuhiro
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (02) : 395 - 400
[9] Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension
Yoshida, Shunji
Shirato, Kunio
Shimamura, Ryutaro
Iwase, Takayuki
Aoyagi, Narumi
Nakajima, Hiromu
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (06) : 1069 - 1076
[10] Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases.
Badesch, D
Zwicke, D
Keogh, AM
Galie, N
Olschewski, H
McGoon, MD
McLaughlin, V
Oudiz, R
Frost, AE
Simonneau, G
Rubin, LJ
ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S166 - S166

← 1 2 3 4 5 →